Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders : Proposal for a Neuroimaging Biomarker Utility System. / van Eimeren, Thilo; Antonini, Angelo; Berg, Daniela; Bohnen, Nico; Ceravolo, Roberto; Drzezga, Alexander; Höglinger, Günter U; Higuchi, Makoto; Lehericy, Stephane; Lewis, Simon; Monchi, Oury; Nestor, Peter; Ondrus, Matej; Pavese, Nicola; Peralta, María Cecilia; Piccini, Paola; Pineda-Pardo, José Ángel; Rektorová, Irena; Rodríguez-Oroz, María; Rominger, Axel; Seppi, Klaus; Stoessl, A Jon; Tessitore, Alessandro; Thobois, Stephane; Kaasinen, Valtteri; Wenning, Gregor; Siebner, Hartwig R.; Strafella, Antonio P; Rowe, James B.

I: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Bind 11, 2019, s. 301-309.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

van Eimeren, T, Antonini, A, Berg, D, Bohnen, N, Ceravolo, R, Drzezga, A, Höglinger, GU, Higuchi, M, Lehericy, S, Lewis, S, Monchi, O, Nestor, P, Ondrus, M, Pavese, N, Peralta, MC, Piccini, P, Pineda-Pardo, JÁ, Rektorová, I, Rodríguez-Oroz, M, Rominger, A, Seppi, K, Stoessl, AJ, Tessitore, A, Thobois, S, Kaasinen, V, Wenning, G, Siebner, HR, Strafella, AP & Rowe, JB 2019, 'Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System', Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, bind 11, s. 301-309. https://doi.org/10.1016/j.dadm.2019.01.011

APA

van Eimeren, T., Antonini, A., Berg, D., Bohnen, N., Ceravolo, R., Drzezga, A., Höglinger, G. U., Higuchi, M., Lehericy, S., Lewis, S., Monchi, O., Nestor, P., Ondrus, M., Pavese, N., Peralta, M. C., Piccini, P., Pineda-Pardo, J. Á., Rektorová, I., Rodríguez-Oroz, M., ... Rowe, J. B. (2019). Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 11, 301-309. https://doi.org/10.1016/j.dadm.2019.01.011

Vancouver

van Eimeren T, Antonini A, Berg D, Bohnen N, Ceravolo R, Drzezga A o.a. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 2019;11:301-309. https://doi.org/10.1016/j.dadm.2019.01.011

Author

van Eimeren, Thilo ; Antonini, Angelo ; Berg, Daniela ; Bohnen, Nico ; Ceravolo, Roberto ; Drzezga, Alexander ; Höglinger, Günter U ; Higuchi, Makoto ; Lehericy, Stephane ; Lewis, Simon ; Monchi, Oury ; Nestor, Peter ; Ondrus, Matej ; Pavese, Nicola ; Peralta, María Cecilia ; Piccini, Paola ; Pineda-Pardo, José Ángel ; Rektorová, Irena ; Rodríguez-Oroz, María ; Rominger, Axel ; Seppi, Klaus ; Stoessl, A Jon ; Tessitore, Alessandro ; Thobois, Stephane ; Kaasinen, Valtteri ; Wenning, Gregor ; Siebner, Hartwig R. ; Strafella, Antonio P ; Rowe, James B. / Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders : Proposal for a Neuroimaging Biomarker Utility System. I: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 2019 ; Bind 11. s. 301-309.

Bibtex

@article{b02909f06c904ff7a020cffa9a911e80,
title = "Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System",
abstract = "Introduction: Therapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying pathology, and the objective assessment of disease progression. However, there currently is not yet a consensus in the field on how to describe utility of biomarkers for clinical trials in atypical parkinsonian disorders.Methods: To promote standardized use of neuroimaging biomarkers for clinical trials, we aimed to develop a conceptual framework to characterize in more detail the kind of neuroimaging biomarkers needed in atypical parkinsonian disorders, identify the current challenges in ascribing utility of these biomarkers, and propose criteria for a system that may guide future studies.Results: As a consensus outcome, we describe the main challenges in ascribing utility of neuroimaging biomarkers in atypical parkinsonian disorders, and we propose a conceptual framework that includes a graded system for the description of utility of a specific neuroimaging measure. We included separate categories for the ability to accurately identify an intention-to-treat patient population early in the disease (Early), to accurately detect a specific underlying pathology (Specific), and the ability to monitor disease progression (Progression).Discussion: We suggest that the advancement of standardized neuroimaging in the field of atypical parkinsonian disorders will be furthered by a well-defined reference frame for the utility of biomarkers. The proposed utility system allows a detailed and graded description of the respective strengths of neuroimaging biomarkers in the currently most relevant areas of application in clinical trials.",
author = "{van Eimeren}, Thilo and Angelo Antonini and Daniela Berg and Nico Bohnen and Roberto Ceravolo and Alexander Drzezga and H{\"o}glinger, {G{\"u}nter U} and Makoto Higuchi and Stephane Lehericy and Simon Lewis and Oury Monchi and Peter Nestor and Matej Ondrus and Nicola Pavese and Peralta, {Mar{\'i}a Cecilia} and Paola Piccini and Pineda-Pardo, {Jos{\'e} {\'A}ngel} and Irena Rektorov{\'a} and Mar{\'i}a Rodr{\'i}guez-Oroz and Axel Rominger and Klaus Seppi and Stoessl, {A Jon} and Alessandro Tessitore and Stephane Thobois and Valtteri Kaasinen and Gregor Wenning and Siebner, {Hartwig R.} and Strafella, {Antonio P} and Rowe, {James B.}",
year = "2019",
doi = "10.1016/j.dadm.2019.01.011",
language = "English",
volume = "11",
pages = "301--309",
journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",
issn = "2352-8729",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders

T2 - Proposal for a Neuroimaging Biomarker Utility System

AU - van Eimeren, Thilo

AU - Antonini, Angelo

AU - Berg, Daniela

AU - Bohnen, Nico

AU - Ceravolo, Roberto

AU - Drzezga, Alexander

AU - Höglinger, Günter U

AU - Higuchi, Makoto

AU - Lehericy, Stephane

AU - Lewis, Simon

AU - Monchi, Oury

AU - Nestor, Peter

AU - Ondrus, Matej

AU - Pavese, Nicola

AU - Peralta, María Cecilia

AU - Piccini, Paola

AU - Pineda-Pardo, José Ángel

AU - Rektorová, Irena

AU - Rodríguez-Oroz, María

AU - Rominger, Axel

AU - Seppi, Klaus

AU - Stoessl, A Jon

AU - Tessitore, Alessandro

AU - Thobois, Stephane

AU - Kaasinen, Valtteri

AU - Wenning, Gregor

AU - Siebner, Hartwig R.

AU - Strafella, Antonio P

AU - Rowe, James B.

PY - 2019

Y1 - 2019

N2 - Introduction: Therapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying pathology, and the objective assessment of disease progression. However, there currently is not yet a consensus in the field on how to describe utility of biomarkers for clinical trials in atypical parkinsonian disorders.Methods: To promote standardized use of neuroimaging biomarkers for clinical trials, we aimed to develop a conceptual framework to characterize in more detail the kind of neuroimaging biomarkers needed in atypical parkinsonian disorders, identify the current challenges in ascribing utility of these biomarkers, and propose criteria for a system that may guide future studies.Results: As a consensus outcome, we describe the main challenges in ascribing utility of neuroimaging biomarkers in atypical parkinsonian disorders, and we propose a conceptual framework that includes a graded system for the description of utility of a specific neuroimaging measure. We included separate categories for the ability to accurately identify an intention-to-treat patient population early in the disease (Early), to accurately detect a specific underlying pathology (Specific), and the ability to monitor disease progression (Progression).Discussion: We suggest that the advancement of standardized neuroimaging in the field of atypical parkinsonian disorders will be furthered by a well-defined reference frame for the utility of biomarkers. The proposed utility system allows a detailed and graded description of the respective strengths of neuroimaging biomarkers in the currently most relevant areas of application in clinical trials.

AB - Introduction: Therapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying pathology, and the objective assessment of disease progression. However, there currently is not yet a consensus in the field on how to describe utility of biomarkers for clinical trials in atypical parkinsonian disorders.Methods: To promote standardized use of neuroimaging biomarkers for clinical trials, we aimed to develop a conceptual framework to characterize in more detail the kind of neuroimaging biomarkers needed in atypical parkinsonian disorders, identify the current challenges in ascribing utility of these biomarkers, and propose criteria for a system that may guide future studies.Results: As a consensus outcome, we describe the main challenges in ascribing utility of neuroimaging biomarkers in atypical parkinsonian disorders, and we propose a conceptual framework that includes a graded system for the description of utility of a specific neuroimaging measure. We included separate categories for the ability to accurately identify an intention-to-treat patient population early in the disease (Early), to accurately detect a specific underlying pathology (Specific), and the ability to monitor disease progression (Progression).Discussion: We suggest that the advancement of standardized neuroimaging in the field of atypical parkinsonian disorders will be furthered by a well-defined reference frame for the utility of biomarkers. The proposed utility system allows a detailed and graded description of the respective strengths of neuroimaging biomarkers in the currently most relevant areas of application in clinical trials.

U2 - 10.1016/j.dadm.2019.01.011

DO - 10.1016/j.dadm.2019.01.011

M3 - Journal article

C2 - 30984816

VL - 11

SP - 301

EP - 309

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

SN - 2352-8729

ER -

ID: 224654790